Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PaclEVin in Advanced Cancer and Metastatic Prostate Cancer
NCT00004105Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Sep 1998
- Primary completion
- Apr 2003
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, estramustine and vinorelbine in cancer and Metastatic Prostate Cancer (mPC), sponsored by NYU Langone Health. Primary endpoints: Maximum Tolerated Dose, Recommended Phase II Dose and 2 more. Started Sep 1998; status: completed.
02
Drugs
paclitaxelestramustinevinorelbine
03
Conditions
cancerMetastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on NCT00004105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004105.